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Polyfluoroalkyl chemicals (PFCs) are a class 
of highly stable man-made compounds. 
Composed of a variable-length fluorinated 
carbon backbone and a carboxylate or sul-
fonate functional group, PFCs have both 
hydrophobic and oleophobic portions that 
enable products to repel both oil and water 
and resist staining. PFCs are widely used 
in industrial applications as surfactants and 
emulsifiers and in consumer products such as 
food packaging, nonstick pan coatings, fire-
fighting foams, paper and textile coatings, and 
personal care products (Calafat et al. 2007b; 
Renner 2001).
PFCs are extremely resistant to envi-
ronmental and metabolic degradation and 
have been detected globally in the environ-
ment and wildlife (Lau et al. 2007). PFCs 
have been measured in the blood of occu-
pationally exposed cohorts and in the gen-
eral population. The source of PFCs in the 
general population is likely to be environ-
mental exposure to individual PFCs or their 
precursor molecules; however, the specific 
source contributions are not well character-
ized. PFCs released during manufacturing 
processes or in wastes from the perfluoroalkyl 
industry are potential sources of exposure for 
the individuals employed in these industries 
as well as for the general population (3M 
Company 2003). Other potential sources of 
exposure include consumer products con-
taining PFCs, contaminated drinking and 
surface waters, airborne PFCs, indoor air, and 
house dust (3M Company 2003; Boulanger 
et al. 2004; Emmett et al. 2006; Holzer et al. 
2008; Martin et al. 2002; Saito et al. 2004; 
Shoeib et al. 2005; So et al. 2004; Steenland 
et al. 2009; Stock et al. 2004).
PFCs are absorbed through ingestion 
and to a lesser extent through inhalation. 
Once absorbed, PFCs are eliminated from 
the human body very slowly. Serum half-life 
estimates in an occupationally exposed cohort 
ranged from 5.4 years for perfluorooctane 
sulfonic acid (PFOS) to 8.5 years for per-
fluorohexane sulfonic acid (PFHxS) (Olsen 
et al. 2007). In a cohort exposed to drinking 
water contaminated by perfluorooctanoic acid 
(PFOA), the serum half-life for PFOA was 
estimated to be 2.3 years (Bartell et al. 2010). 
Although the primary producer of PFOS, 
the 3M Company, discontinued its use in 
2002; and U.S. companies have implemented 
a voluntary emission reduction program for 
PFOA, > 98% of a 2003–2004 U.S. popula-
tion sample had detectable serum levels of 
two perfluorinated carboxylates, PFOA and 
perfluorononanoic acid (PFNA), and two 
perfluorinated sulfonates, PFOS and PFHxS 
(Calafat et al. 2007b).
The ubiquitous presence and persistence 
of PFCs in the environment and the human 
body have led to efforts to understand the 
toxicologic hazards that may be associated 
with exposure. Early animal studies focused 
almost exclusively on exposure to PFOS and 
PFOA and found several potential effects, 
primarily related to hepatotoxicity, immuno-
toxicity, and reproductive and developmental 
toxicity (Lau et al. 2004, 2007). Although 
assessments are now including other PFCs 
and examining human populations, data are 
still limited.
Preliminary data suggest that PFCs may 
be potential developmental neurotoxicants. 
Using in vitro models, PFCs were shown to 
affect neuronal cell development in a variety 
of ways, including changes in cell differen-
tiation (Slotkin et al. 2008). In rat models, 
in utero exposure to PFOS was linked to 
reduction in thyroid hormone (circulating 
thyroxin and triiodothyronine), which is 
known to regulate brain development (Lau 
et al. 2003; Luebker et al. 2005). However, in 
pups exposed to PFOS prenatally, reductions 
in thyroid hormone did not appear to disrupt 
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Background: Polyfluoroalkyl chemicals (PFCs) have been widely used in consumer products. 
Exposures in the United States and in world populations are widespread. PFC exposures have been 
linked to various health impacts, and data in animals suggest that PFCs may be potential develop‑
mental neurotoxicants.
oBjectives: We evaluated the associations between exposures to four PFCs and parental report of 
diagnosis of attention deficit/hyperactivity disorder (ADHD).
Methods: Data were obtained from the National Health and Nutrition Examination Survey 
(NHANES) 1999–2000 and 2003–2004 for children 12–15 years of age. Parental report of a 
previous diagnosis by a doctor or health care professional of ADHD in the child was the primary 
outcome measure. Perfluorooctane sulfonic acid (PFOS), perfluorooctanoic acid (PFOA), perfluo‑
rononanoic acid (PFNA), and perfluorohexane sulfonic acid (PFHxS) levels were measured in serum 
samples from each child.
results: Parents reported that 48 of 571 children included in the analysis had been diagnosed with 
ADHD. The adjusted odds ratio (OR) for parentally reported ADHD in association with a 1‑μg/L 
increase in serum PFOS (modeled as a continuous predictor) was 1.03 [95% confidence interval 
(CI), 1.01–1.05]. Adjusted ORs for 1‑μg/L increases in PFOA and PFHxS were also statistically sig‑
nificant (PFOA: OR = 1.12; 95% CI, 1.01–1.23; PFHxS: OR = 1.06; 95% CI, 1.02–1.11), and we 
observed a nonsignificant positive association with PFNA (OR = 1.32; 95% CI, 0.86–2.02).
conclusions: Our results, using cross‑sectional data, are consistent with increased odds of ADHD 
in children with higher serum PFC levels. Given the extremely prevalent exposure to PFCs, follow‑
up of these data with cohort studies is needed.
key words: attention deficit/hyperactivity disorder (ADHD), National Health and Nutrition 
Examination Survey (NHANES), perfluorohexane sulfonic acid (PFHxS), perfluorononanoic acid 
(PFNA), perfluorooctane sulfonic acid (PFOS), perfluorooctanoic acid (PFOA), polyfluoroalkyl 
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learning and memory behavior in postnatal 
evaluations (Lau et al. 2003). Other devel-
opmental neurotoxic effects, manifested in 
changes in motor function and delayed learn-
ing, were observed in several animal studies 
(Fuentes et al. 2007a, 2007b; Johansson et al. 
2008). Even at relatively low doses, Johansson 
et al. (2008) found developmental neurotoxic 
effects, including changes in spontaneous 
behavior and habituation ability, associated 
with PFOA and PFOS exposure in mice, 
which persisted into adulthood. Neonatal 
exposure to PFOS and PFOA has also been 
associated with changes in proteins (tau and 
synaptophysin) important in normal brain 
development (Johansson et al. 2009). To our 
knowledge, a single reported study assessed 
the human developmental neurotoxic effects 
of exposure to PFOA and PFOS. Using data 
for 1,400 pairs of pregnant women and their 
children randomly selected from the Danish 
National Birth Cohort, Fei et al. (2008) 
observed an association between maternal 
PFOS levels and delayed gross motor devel-
opment in infancy (maternal report of the age 
at which a child could sit without support); 
however, maternal PFOS and PFOA levels 
were not significantly associated with delays 
in other developmental milestones, including 
those related to attention. 
Attention deficit/hyperactivity disorder 
(ADHD) is one of the most common neu-
rodevelopmental disorders in children, with 
an estimated prevalence between 7% and 16% 
in the United States (Faraone et al. 2003; 
Froehlich et al. 2007). Data suggest that the 
underlying prevalence of ADHD is increasing. 
Children diagnosed with ADHD are a hetero-
geneous population sharing common symp-
toms, including inattention, impulsivity, and, 
in some cases, hyperactivity, or a combination 
of symptoms. Although the mechanisms that 
lead to the development of ADHD remain 
unclear, genetic and environmental factors 
have been linked to ADHD. Environmental 
contaminants such as methylmercury and lead 
have been positively associated with ADHD 
in children (Braun et al. 2006; Cheuk and 
Wong 2006).
In the present analyses, we explored the 
association between ADHD and PFOS, 
PFOA, PFHxS, and PFNA using cross-
 sectional data from the National Health and 
Nutrition Examination Survey (NHANES) 
1999–2000 and 2003–2004 cycles. To our 
knowledge, this is the first study examining 
the association between PFCs and ADHD.
Methods
Data source. NHANES is a nationally repre-
sentative, cross-sectional sample of the non-
institutionalized U.S. civilian population. 
The survey combines in-home interviews 
and physical examinations in a mobile exam 
unit to collect data on demographics, socio-
economic status (SES), health conditions, 
and behavioral and environmental risk factors 
[Centers for Disease Controls and Prevention 
(CDC) 2008]. Details regarding interviews, 
examination procedures, and sample collec-
tion have been described previously (CDC 
2009a, 2009b).
ADHD and PFC exposure assessment. 
We used parental report of previous ADHD 
diagnosis as the primary dependent variable. 
Questionnaires were administered by trained 
personnel (CDC 2009a, 2009b). The chil-
dren’s parents or guardians were asked if a 
doctor or health professional had ever told 
them that their child had attention deficit 
disorder. In NHANES, data on ADHD were 
collected in a target population of children 
4–19 years of age.
To improve specificity, we also considered 
a second definition of ADHD used previously 
in an assessment of the effects of other envi-
ronmental exposures on ADHD risk in the 
NHANES population (Braun et al. 2006). 
The second case definition included children 
with a parental report of a previous ADHD 
diagnosis and a parental report of their child 
taking medications approved for the treatment 
of ADHD within the preceding month (e.g., 
amphetamine aspartate, amphetamine sulfate, 
dextroamphetamine saccharate, dextroamphet-
amine sulfate, methylphenidate hydrochloride, 
or atomoxetine hydrochloride).
The National Center for Environmental 
Health analyzed serum PFC levels in a one-
third sample of all individuals ≥ 12 years of age. 
Data were available during two nonconsecutive 
survey cycles, 1999–2000 and 2003–2004. 
Detailed analytic methods were described pre-
viously (Calafat et al. 2007a, 2007b). Briefly, 
serum samples were analyzed using automated 
solid-phase extraction coupled to reverse-phase 
high-performance liquid chromatography/ 
tandem mass spectrometry. Any subject with 
a serum PFC concentration below the limit 
of detection (LOD) was assigned an exposure 
value of the LOD divided by the square root 
of 2 (Calafat et al. 2007b).
Covariates. We investigated a number of 
covariates and potential confounders in the 
association between PFCs and ADHD. The 
demographic variables age, sex, and race/ 
ethnicity were included as covariates based on 
their role in the NHANES selection procedure 
and previous research on their association with 
ADHD (Costello et al. 2003; Stevens et al. 
2005). Additionally, we included NHANES 
sample cycle (1999–2000 or 2003–2004) as a 
covariate. SES was also considered a potential 
confounder. We used the poverty–income 
ratio (PIR), which relates the family income 
to the poverty threshold for each study year as 
a measure of SES. PIR values < 1.00 are con-
sidered living below the poverty level. Having 
a routine health care provider and health 
insurance coverage were also considered 
potential confounders (Stevens et al. 2005). 
In addition, we also investigated confounding 
by other environmental contaminants that 
have been previously associated with ADHD: 
lead and environmental tobacco smoke (ETS) 
indicated by report of living with someone 
who smokes cigarettes, cigars, or pipes inside 
the home and by serum cotinine, a metabo-
lite of nicotine (Bellinger et al. 1994; Braun 
et al. 2006; Fergusson et al. 1988; Weitzman 
et al. 1992; Williams et al. 1998). We also 
considered confounding by variables related 
to conditions during the prenatal and early 
childhood periods: birth weight, admittance 
to a neonatal intensive care unit (NICU), 
maternal smoking during pregnancy, and 
preschool attendance (Botting et al. 1997; 
Braun et al. 2006; Mick et al. 2002a, 2002b; 
Milberger et al. 1996; National Institute of 
Child Health and Human Development 
2003). NHANES collects different exposure, 
outcome, and confounder data depending 
on the age of the individual. Data on ADHD 
outcomes, confounder information, and PFC 
measurements were collected for children 
12–15 years of age only; consequently, analy-
ses were limited to this age range.
Statistical analyses. We examined the 
shape of the relationship between the con-
tinuous measures of each individual PFC 
and parent-reported ADHD using a locally 
weighted regression smoother (LOESS) in 
S-Plus (version 8.0; Tibco Software, Inc., Palo 
Alto, CA). Smoothing allowed us to sum-
marize ADHD odds as a function of PFC 
exposures without imposing a rigid form of 
dependence. We selected the optimal span 
size—the window from which data are drawn 
to estimate the odds of ADHD—by minimiz-
ing Akaike’s information criterion (Hastie and 
Tibshirani 1990). We visually inspected plots 
of the smoothed data to inform our decision 
on how to model exposure.
Logistic regression analyses were performed 
in SAS (version 9.1; SAS Institute, Inc., Cary, 
NC) using the Proc SURVEYLOGISTIC 
procedure, which accounts for stratification 
and clustering within primary sampling units 
used to select the NHANES sample. Rather 
than using NHANES sample weights, we 
adjusted all models for relevant covariates 
(age, sex, race/ethnicity, and sample cycle). 
This method is considered to be a good trade-
off between efficiency and bias (Graubard and 
Korn 1999; Korn and Graubard 1991). Other 
potential covariates were included if they were 
strongly associated with ADHD in bivari-
ate analyses (p < 0.10) or if they appreciably 
altered the association between PFC exposure 
and ADHD [odds ratio (OR) change > 10%]. 
We included continuous covariates in models 
as continuous predictors and also explored 
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the use of categorization. A p-value of 0.05 
was chosen to indicate the statistical signifi-
cance of the association between each PFC 
and ADHD.
Our preliminary investigation of PFC 
data revealed several children with very high 
serum PFC levels, particularly PFHxS, PFOA, 
and PFNA. To ensure that individuals with 
extreme exposure values were not dispropor-
tionately influencing results, we conducted 
sensitivity analyses excluding observations 
greater than three times the 75th percentile for 
each compound (PFOS, n = 0; PFOA, n = 2; 
PFNA, n = 12; PFHxS, n = 26). Additionally, 
because the range of serum values varied con-
siderably for the PFCs we assessed, we con-
ducted additional analyses to provide ORs 
standardized to an increase in units equal to 
the interquartile range (IQR) for each PFC to 
provide comparable effect estimates.
We also investigated the impact of all four 
PFCs in the same model. Because PFC levels 
are correlated (in these data, Spearman corre-
lations ranged from 0.18 between PFOS and 
PFNA to 0.74 between PFOS and PFOA), we 
also performed principal component analysis, 
a systematic method of reducing the number 
of correlated observed variables into a smaller 
number of principal components that account 
for most of the variance in the observed PFC 
measures (Burstyn 2004).
Results
Of the 571 study participants 12–15 years 
of age with complete data, parents of 48 
(8.4%) reported that their child had ADHD. 
Of those, 21 (3.6% of the study population) 
also reported using prescription medica-
tions approved for the treatment of ADHD 
within the last month. We included one child 
reported to be taking prescription medication 
for ADHD but not reported to have been 
diagnosed with ADHD in analyses as a non-
case. Details regarding the total sample size 
are displayed in the Supplemental Material, 
Figure 1 (doi:10.1289/ehp.1001898).
Sex and maternal smoking during preg-
nancy were significantly associated with 
parental-report of ADHD in bivariate analy-
ses (Table 1). Compared with non-Hispanic 
whites, Mexican Americans were less likely 
to report ADHD diagnosis [OR = 0.28; 
95% confidence interval (CI), 0.11–0.72]. 
Associations between ETS and ADHD were 
similar whether ETS was indicated by cate-
gorical serum cotinine levels (data not shown) 
or report of living with someone who smokes 
cigarettes, cigars, or pipes inside the home. 
We controlled for ETS in models using report 
of living in a home with a smoker because 
data were missing less frequently. ETS was not 
associated with our stricter case definition of 
ADHD, having a reported diagnosis and tak-
ing prescription medication for the treatment 
of ADHD, which was similar to what Braun 
et al. (2006) observed. We also observed a 
positive association between lead and ADHD 
similar to that reported previously in a larger 
NHANES sample (Braun et al. 2006).
Table 2 displays the median serum level of 
each PFC in the study population. Nearly all 
study participants had detectable serum con-
centrations of all four PFCs included in our 
analyses (> 96% for all PFCs). Other PFCs 
were detected infrequently in this population. 
Table 3 displays the median serum PFC levels 
according to categorical covariates. Median 
serum concentrations were consistently higher 
in males than females and in children who 
attended preschool. Similarly, those who lived 
in a home with a smoker consistently had 
higher PFC levels. Table 4 displays correla-
tions between continuous covariates and each 
PFC. With the exception of PFOA, which 
was weakly correlated with lead, we did not 
observe evidence of an association between 
PFCs and lead. Additionally, we observed a 
small but significant correlation between each 
PFC and the PIR.
The results of the smoothed analyses sug-
gested that the association between PFC lev-
els and ADHD may be approximately linear 
over most of the data range; accordingly, we 
included PFCs in logistic regression mod-
els as continuous predictors [see details in 
Supplemental Material, Figure 2 (doi:10.1289/
ehp.1001898)]. We observed a significant 
(p-value < 0.05) dose–response relationship 
between PFOS exposure and parent-reported 
ADHD; the OR for each 1-μg/L increase in 
serum PFOS was 1.03 (95% CI, 1.01–1.05) 
(Table 5) after adjusting for confounding by 
Table 1. Selected population characteristics and bivariate analyses of parental-reported ADHD and 
covariates.
Variable Cases Noncases OR (95% CI)
Age [mean (years)] 13.4 13.4 0.93 (0.73–1.18)
Sex (n)
Male 41 255 4.50 (2.17–9.37)
Female 10 280 Reference
Race/ethnicity (n)
Mexican American 9 206 0.28 (0.11–0.72)
Other Hispanic 1 25 0.26 (0.03–2.11)
Non-Hispanic white 18 116 Reference
Non-Hispanic black 20 164 0.79 (0.35–1.76)
Other, including multiracial 3 24 0.81 (0.28–2.33)
Birth weight (n)a,b
≤ 5.5 lb (2,500 g) 4 26 1.57 (0.62–4.02)
> 5.5 lb (2,500 g) 47 481 Reference
Maternal smoking during pregnancy (n)a
Yes 13 80 2.08 (1.04–4.17)
No 35 448 Reference
Preschool attendance (n)a
Yes 37 341 1.50 (0.84–2.68)
No 14 193 Reference
NICU admittance (n)
Yes 8 60 1.45 (0.83–2.53)
No 43 467 Reference
ETS (n)c
Yes 22 117 2.68 (1.58–4.53)
No 29 413 Reference
Lead [mean (μg/dL)]a 1.5 1.3 1.09 (0.90–1.34)
PIR (mean)a 1.8 1.9 1.08 (0.94–1.23)
Access to health care (n)d
Yes 49 495 1.98 (0.71–5.49)
No 2 40 Reference
Health insurance coverage (n)a
Yes 46 427 2.15 (0.83–5.57)
No 5 100 Reference
NHANES sample wave (n) 
1999–2000 20 258 Reference
2003–2004 31 277 1.44 (0.84–2.48)
aMissing data: low birth weight, n = 28; maternal smoking during pregnancy, n = 10; preschool attendance, n = 1; ETS, 
n = 5; lead, n = 1; PIR, n = 35; health insurance coverage, n = 8. bLow birth weight defined as ≤ 5.5 lb or 2,500 g. cReport of 
living in a home with someone who smokes cigarettes, cigars, or pipes inside. dParents reported that the child had one 
or more places to go when they were sick or need advice about health.
Table 2. Distribution of PFC levels in the study 
population (μg/L).
Variable Median Range IQR
PFOS 22.6 2.1–87.2 15.9
PFOA 4.4 0.4–21.7 2.7
PFHxS 2.2 ND to 64.1 2.9
PFNA 0.6 ND to 5.9 0.5
ND, nondetectable. The LOD in 1999–2000 serum samples 
was 0.2 μg/L for PFOS, 0.1 μg/L for PFOA, 0.1 μg/L for 
PFHxS, and 0.1 μg/L for PFNA; in 2003–2004 serum sam-
ples, it was 0.4 μg/L for PFOS, 0.1 μg/L for PFOA, 0.3 μg/L 
for PFHxS, and 0.1 μg/L for PFNA (Calafat et al. 2007b).
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NHANES sample cycle, age, race/ethnic-
ity, sex, ETS, and maternal smoking during 
pregnancy. Crude estimates of the associa-
tion between PFCs and ADHD were similar 
to adjusted estimates. The inclusion of other 
covariates, including the PIR, did not materi-
ally alter the association between PFCs and 
parent-reported ADHD (data not shown). 
PFOA and PFHxS levels were also positively 
associated with ADHD (PFOA: OR = 1.12; 
95% CI, 1.01–1.23; PFHxS: OR = 1.06; 95% 
CI, 1.02–1.11). The odds of parent-reported 
ADHD also increased with PFNA concentra-
tions, although not significantly (OR = 1.32; 
95% CI, 0.86–2.02). Results were similar 
when we used the stricter case definition of 
ADHD that required both parental report and 
medication use (Table 5). The same covariates 
were evaluated for each case definition.
Because the range of serum values var-
ied considerably for the PFCs we assessed, 
we also calculated ORs standardized to an 
increase in units equal to the IQR for each 
PFC. An increase in serum PFOS levels equal 
to the IQR was associated with 1.60 times 
the odds of ADHD (95% CI, 1.10–2.31; 
IQR = 15.9 μg/L). For PFOA, the odds of 
ADHD increased 1.35 times for an increase 
equal to the IQR (95% CI, 1.04–1.77; IQR 
= 2.7 μg/L). A 2.9-μg/L increase in serum 
PFHxS increased the odds of ADHD 1.19 
times (95% CI, 1.05–1.34). The IQR effect 
for PFNA increased ADHD odds 1.15 times 
(95% CI, 0.93–1.42; IQR = 0.5 μg/L).
Several children had very high serum 
PFC levels, particularly PFHxS, PFOA, and 
PFNA. Estimated ORs were slightly higher 
than those reported in Table 5 when obser-
vations with PFC concentrations more than 
three times the value of the 75th percentile 
were excluded (data not shown).
Principal component analyses indicated 
that PFOS, PFOA, and PFHxS all loaded onto 
a single component that accounted for 58% of 
the total variability in all four PFC measures. 
A second component, which primarily repre-
sented PFNA exposure, accounted for an addi-
tional 22% of the total variability. We repeated 
multiple logistic regression analyses includ-
ing both PFNA and the principal component 
that represented the weighted combination of 
PFOS, PFOA, and PFHxS. A positive associa-
tion with ADHD remained for the combined 
PFC variable and for PFNA (data not shown; 
PFOS, PFOA, and PFHxS component p-value 
= 0.02; PFNA p-value = 0.72).
Discussion
We observed a positive dose–response rela-
tionship between parent-reported ADHD 
and serum PFOS, PFOA, and PFHxS con-
centrations modeled as continuous predictors. 
Including PFC levels modeled as categorical 
predictors of ADHD produced similar results. 
The estimated effect of exposure on the pop-
ulation level was similar across these PFCs 
based on IQR analyses, indicating the impor-
tance of extending neurotoxicologic research 
to PFCs other than PFOS and PFOA, which 
have historically been the focus of research.
Principal component analyses support 
evidence of a positive association between 
ADHD and serum PFCs. Controlling for 
PFNA levels and other covariates, we observed 
a significant positive association with the prin-
cipal component representing PFOS, PFOA, 
and PFHxS, suggesting that there may be dif-
ferent sources of exposure for PFNA and the 
other PFCs that we assessed. This is an area 
for future research.
Our results are consistent with animal data 
that suggest neurotoxic effects of PFC expo-
sures (Fuentes et al. 2007a, 2007b; Johansson 
et al. 2008). To our knowledge, the report by 
Fei et al. (2008) is the only other published 
study of neurodevelopmental outcomes and 
PFC exposures. Except for gross motor ability, 
Fei et al. (2008) did not observe statistically 
significant differences in maternal reports of 
developmental milestones in infancy related 
to PFOS or PFOA exposure. The age of indi-
viduals in the study populations may explain 
Table 3. Median serum PFC concentrations (μg/L) by categorical covariates.
Variable n PFOS PFOA PFHxS PFNA
Sex
Male 296 23.7 4.8 2.5 0.7
Female 290 21.9 4.0 2.0 0.6
Race/ethnicity
Mexican American 215 20.0 4.1 1.7 0.4
Other Hispanic 26 18.8 4.4 1.3 0.5
Non-Hispanic white 134 26.3 4.6 3.3 0.7
Non-Hispanic black 184 24.1 4.6 2.4 0.8
Other, including multiracial 27 24.6 4.1 2.7 0.5
Birth weighta
≤ 5.5 lb (2,500 g) 30 22.0 3.8 2.3 0.7
> 5.5 lb (2,500 g) 528 22.7 4.4 2.2 0.6
Maternal smoking during pregnancy
Yes 93 22.8 4.4 2.6 0.7
No 483 22.5 4.1 2.1 0.6
Preschool attendancea
Yes 378 23.5 4.5 2.4 0.7
No 207 21.1 4.1 1.8 0.5
NICU admittance
Yes 68 22.4 4.5 2.5 0.6
No 510 22.6 4.4 2.2 0.6
ETSa
Yes 139 24.7 4.5 2.3 0.7
No 442 22.2 4.3 2.1 0.6
Access to health care
Yes 544 23.0 4.4 2.3 0.6
No 42 18.4 3.5 1.4 0.4
Health insurance coveragea
Yes 473 23.4 4.4 2.3 0.6
No 105 18.8 3.9 1.6 0.4
NHANES sample wave
1999–2000 278 28.2 5.3 2.2 0.4
2003–2004 308 18.2 3.8 2.2 0.8
aMissing data: low birth weight, n = 28; maternal smoking during pregnancy, n = 10; preschool attendance, n = 1; ETS, 
n = 5; health insurance coverage, n = 8.
Table 4. Spearman correlations between continuous covariates and PFCs (p-value).
Variable PFOS PFOA PFHxS PFNA
Age (years) –0.078 (0.059) –0.051 (0.220) –0.052 (0.208) 0.008 (0.852)
Leada 0.062 (0.133) 0.121 (0.003) 0.033 (0.428) 0.030 (0.464)
PIRa 0.233 (< 0.001) 0.172 (< 0.001) 0.178 (< 0.001) 0.169 (< 0.001)
aMissing data: lead, n = 1; PIR, n = 35. 
Table 5. ORs (95% CIs) for 1-μg/L increase in serum level (n = 571).
Parental report of ADHD With prescription 
medication use (adjusted)aCrude Adjusteda
PFOS 1.03 (1.01–1.05) 1.03 (1.01–1.05) 1.05 (1.02–1.08)
PFOA 1.17 (1.07–1.30) 1.12 (1.01–1.23) 1.19 (0.95–1.49)
PFHxS 1.07 (1.01–1.12) 1.06 (1.02–1.11) 1.07 (1.03–1.11)
PFNA 1.76 (1.39–2.23) 1.32 (0.86–2.02) 1.57 (0.67–3.64)
aAdjusted for NHANES sample cycle, age, sex, race, ETS, and maternal smoking during pregnancy.
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the difference between our results and those 
reported by Fei et al. (2008). Because of data 
availability, we were able to assess only chil-
dren 12–15 years of age.
Our analyses have a number of limita-
tions. NHANES data are collected cross-
 sectionally, making it difficult to infer a causal 
relationship between PFC levels and ADHD. 
These data do not allow us to speculate on 
potential development periods of suscepti-
bility to exposure. Although PFCs have a 
relatively long half-life, there is a lack of infor-
mation addressing whether current PFC levels 
are an appropriate surrogate for past levels in 
the general population (Bartell et al. 2010; 
Olsen et al. 2007). If the prenatal period and 
early childhood, when the developing brain 
may be more susceptible, are the critical peri-
ods for insult from PFC exposure, then ran-
dom misclassification error resulting from the 
use of current PFC levels as proxy measures 
of etiologically relevant exposures may have 
biased our results toward the null.
These analyses are also potentially limited 
by our reliance on parental report of ADHD. 
Previous research indicates parental reports 
of ADHD are highly reliable (Faraone et al. 
1995). Examining the combined outcome 
of reported ADHD and medication use, we 
improved the specificity of the outcome and 
increased the likelihood that children included 
as ADHD cases had been evaluated and treated 
by health care professionals. Although we iden-
tified a much smaller number of cases using the 
stricter definition (n = 21), and consequently 
reduced the precision, the point estimates were 
similar regardless of which case definition was 
used. Similarly, although we included a large 
number of terms in models for a relatively small 
number of outcomes, crude estimates of the 
association between PFCs and ADHD were 
similar to adjusted estimates. Analyses of the 
NHANES population conducted previously 
have shown that parental report of ADHD was 
related to other environmental exposures (e.g., 
lead and maternal smoking during pregnancy) 
(Braun et al. 2006).
Detailed questionnaire and laboratory 
measurement data were available for a num-
ber of potential covariates in the NHANES 
data set, and we able to evaluate the poten-
tial for confounding by conditions during 
the prenatal and early childhood periods and 
other environmental exposures, such as lead 
and SES, related to ADHD. Data for poten-
tial confounders were generally very com-
plete. However, there may still be residual 
confounding in the association between PFCs 
and ADHD. We were unable to assess sev-
eral potential confounders because they were 
either not publically available (i.e., maternal 
alcohol consumption during pregnancy) or 
not collected in the NHANES data set (i.e., 
genetic predisposition for ADHD).
Despite these limitations, our analyses 
have a number of strengths including the use 
of a representative sample of the U.S. pop-
ulation. Additionally, we were able to con-
sider the association between PFC levels and 
ADHD odds over a wide range of exposures. 
We were also able to estimate associations 
of PFNA and PFHxS with ADHD; to our 
knowledge, this is the first assessment of the 
potential developmental neurotoxicity of these 
PFCs in children.
Conclusions
To our knowledge, these analyses are the first 
to assess the association between PFC lev-
els and ADHD. As a whole, our results are 
consistent with increased ADHD in children 
with higher serum levels of PFCs. Given the 
extremely prevalent exposure to PFCs, further 
investigation into the impact of PFC exposure 
on ADHD and other neurodevelopmental 
endpoints is warranted.
RefeRences
3M Company. 2003. Environmental and Health Assessment of 
Perfluorooctane Sulfonic Acid and Its Salts. AR 226-1486. 
St Paul, MN:3M Company.
Bartell SM, Calafat AM, Lyu C, Kato K, Ryan B, Steenland K. 
2010. Rate of decline in serum PFOA concentrations 
after granular activated carbon filtration at two public 
water systems in Ohio and West Virginia. Environ Health 
Perspect 118:222–228.
Bellinger D, Leviton A, Allred E, Rabinowitz M. 1994. Pre- and 
postnatal lead exposure and behavior problems in school-
aged children. Environ Res 66(1):12–30.
Botting N, Powls A, Cooke RW, Marlow N. 1997. Attention 
deficit hyperactivity disorders and other psychiatric out-
comes in very low birthweight children at 12 years. J Child 
Psychol Psychiatry 38(8):931–941.
Boulanger B, Vargo J, Schnoor JL, Hornbuckle KC. 2004. 
Detection of perfluorooctane surfactants in Great Lakes 
water. Environ Sci Technol 38(15):4064–4070.
Braun JM, Kahn RS, Froehlich T, Auinger P, Lanphear BP. 2006. 
Exposures to environmental toxicants and attention deficit 
hyperactivity disorder in U.S. children. Environ Health 
Perspect 114:1904–1909.
Burstyn I. 2004. Principal component analysis is a powerful 
instrument in occupational hygiene inquiries. Ann Occup 
Hyg 48(8):655–661.
Calafat AM, Kuklenyik Z, Reidy JA, Caudill SP, Tully JS, 
Needham LL. 2007a. Serum concentrations of 11 poly-
fluoroalkyl compounds in the U.S. population: data from 
the National Health and Nutrition Examination Survey 
(NHANES). Environ Sci Technol 41(7):2237–2242.
Calafat AM, Wong LY, Kuklenyik Z, Reidy JA, Needham LL. 
2007b. Polyfluoroalkyl chemicals in the U.S. population: 
data from the National Health and Nutrition Examination 
Survey (NHANES) 2003–2004 and comparisons with 
NHANES 1999–2000. Environ Health Perspect 115:1596–
1602.
CDC (Centers for Disease Control and Prevention). 2008. 
National Health and Nutrition Examination Survey data.
Available: http:www.cdc.gov/nchs/nhanes.htm [accessed 
14 October 2009].
CDC (Centers for Disease Control and Prevention). 2009a. 
Survey Questionnaires, Examination Components and 
Laboratory Components 2003-2004. Available: http://www.
cdc.gov/nchs/nhanes/nhanes2003-2004/questexam03_04.
htm [accessed 14 October 2009].
CDC (Centers for Disease Control and Prevention). 2009b. 
Survey Questionnaires, Examination Components and 
Laboratory Components 1999-2000. Available: http://www.
cdc.gov/nchs/nhanes/nhanes1999-2000/questexam99_00.
htm [accessed 14 October 2009].
Cheuk DK, Wong V. 2006. Attention-deficit hyperactivity 
disorder and blood mercury level: a case-control study in 
Chinese children. Neuropediatrics 37(4):234–240.
Costello EJ, Mustillo S, Erkanli A, Keeler G, Angold A. 2003. 
Prevalence and development of psychiatric disorders 
in childhood and adolescence. Arch Gen Psychiatry 
60(8):837–844.
Emmett EA, Shofer FS, Zhang H, Freeman D, Desai C, Shaw LM. 
2006. Community exposure to perfluorooctanoate: rela-
tionships between serum concentrations and exposure 
sources. J Occup Environ Med 48(8):759–770.
Faraone SV, Biederman J, Milberger S. 1995. How reliable are 
maternal reports of their children’s psychopathology? One-
year recall of psychiatric diagnoses of ADHD children. 
J Am Acad Child Adolesc Psychiatry 34(8):1001–1008.
Faraone SV, Sergeant J, Gillberg C, Biederman J. 2003. The 
worldwide prevalence of ADHD: is it an American condi-
tion? World Psychiatry 2(2):104–113.
Fei C, McLaughlin JK, Lipworth L, Olsen J. 2008. Prenatal 
exposure to perfluorooctanoate (PFOA) and perfluorooc-
tanesulfonate (PFOS) and maternally reported develop-
mental milestones in infancy. Environ Health Perspect 
116:1391–1395.
Fergusson DM, Fergusson JE, Horwood LJ, Kinzett NG. 1988. 
A longitudinal study of dentine lead levels, intelligence, 
school performance and behaviour. Part III. Dentine lead 
levels and attention/activity. J Child Psychol Psychiatry 
29(6):811–824.
Froehlich TE, Lanphear BP, Epstein JN, Barbaresi WJ, 
Katusic SK, Kahn RS. 2007. Prevalence, recognition, and 
treatment of attention-deficit/hyperactivity disorder in a 
national sample of US children. Arch Pediatr Adolesc Med 
161(9):857–864.
Fuentes S, Colomina MT, Vicens P, Domingo JL. 2007a. 
Influence of maternal restraint stress on the long-lasting 
effects induced by prenatal exposure to perfluorooctane 
sulfonate (PFOS) in mice. Toxicol Lett 171(3):162–170.
Fuentes S, Vicens P, Colomina MT, Domingo JL. 2007b. 
Behavioral effects in adult mice exposed to perfluorooc-
tane sulfonate (PFOS). Toxicology 242(1–3):123–129.
Graubard BI, Korn EL. 1999. Analyzing health surveys 
for  cancer-related objectives. J Natl Cancer Inst 
91(12):1005–1016.
Hastie T, Tibshirani R. 1990. Generalized Additive Models. 
London:Chapman and Hall.
Holzer J, Midasch O, Rauchfuss K, Kraft M, Reupert R, 
Angerer J, et al. 2008. Biomonitoring of perfluorinated 
compounds in children and adults exposed to perfluo-
rooctanoate-contaminated drinking water. Environ Health 
Perspect 116:651–657.
Johansson N, Eriksson P, Viberg H. 2009. Neonatal exposure 
to PFOS and PFOA in mice results in changes in proteins 
which are important for neuronal growth and synaptogen-
esis in the developing brain. Toxicol Sci 108(2):412–418.
Johansson N, Fredriksson A, Eriksson P. 2008. Neonatal expo-
sure to perfluorooctane sulfonate (PFOS) and perfluorooc-
tanoic acid (PFOA) causes neurobehavioural defects in 
adult mice. Neurotoxicology 29(1):160–169.
Korn EL, Graubard BI. 1991. Epidemiologic studies utilizing 
surveys: accounting for the sampling design. Am J Public 
Health 81(9):1166–1173.
Lau C, Anitole K, Hodes C, Lai D, Pfahles-Hutchens A, Seed J. 
2007. Perfluoroalkyl acids: a review of monitoring and toxi-
cological findings. Toxicol Sci 99(2):366–394.
Lau C, Butenhoff JL, Rogers JM. 2004. The developmental tox-
icity of perfluoroalkyl acids and their derivatives. Toxicol 
Appl Pharmacol 198(2):231–241.
Lau C, Thibodeaux JR, Hanson RG, Rogers JM, Grey BE, 
Stanton ME, et al. 2003. Exposure to perfluorooctane sul-
fonate during pregnancy in rat and mouse. II: Postnatal 
evaluation. Toxicol Sci 74(2):382–392.
Luebker DJ, York RG, Hansen KJ, Moore JA, Butenhoff JL. 
2005. Neonatal mortality from in utero exposure to per-
fluorooctanesulfonate (PFOS) in Sprague-Dawley rats: 
dose-response, and biochemical and pharamacokinetic 
parameters. Toxicology 215(1–2):149–169.
Martin JW, Muir DC, Moody CA, Ellis DA, Kwan WC, 
Solomon KR, et al. 2002. Collection of airborne fluorinated 
organics and analysis by gas chromatography/chemical 
ionization mass spectrometry. Anal Chem 74(3):584–590.
Mick E, Biederman J, Faraone SV, Sayer J, Kleinman S. 2002a. 
Case-control study of attention-deficit hyperactivity dis-
order and maternal smoking, alcohol use, and drug use 
during pregnancy. J Am Acad Child Adolesc Psychiatry 
41(4):378–385.
Polyfluoroalkyl chemicals and ADHD
Environmental Health Perspectives • volume 118 | number 12 | December 2010 1767
Mick E, Biederman J, Prince J, Fischer MJ, Faraone SV. 2002b. 
Impact of low birth weight on attention-deficit hyper-
activity disorder. J Dev Behav Pediatr 23(1):16–22.
Milberger S, Biederman J, Faraone SV, Chen L, Jones J. 1996. 
Is maternal smoking during pregnancy a risk factor for 
attention deficit hyperactivity disorder in children? Am J 
Psychiatry 153(9):1138–1142.
National Institute of Child Health and Human Development. 
2003. Does amount of time spent in child care predict 
socioemotional adjustment during the transition to kinder-
garten? Child Dev 74(4):976–1005.
Olsen GW, Burris JM, Ehresman DJ, Froehlich JW, Seacat AM, 
Butenhoff JL, et al. 2007. Half-life of serum elimination of 
perfluorooctanesulfonate, perfluorohexanesulfonate, and 
perfluorooctanoate in retired fluorochemical production 
workers. Environ Health Perspect 115:1298–1305.
Renner R. 2001. Growing concern over perfluorinated chemi-
cals. Environ Sci Technol 35(7):154A–160A.
Saito N, Harada K, Inoue K, Sasaki K, Yoshinaga T, Koizumi A. 
2004. Perfluorooctanoate and perfluorooctane sulfonate 
concentrations in surface water in Japan. J Occup Health 
46(1):49–59.
Shoeib M, Harner T, Wilford BH, Jones KC, Zhu J. 2005. 
Perfluorinated sulfonamides in indoor and outdoor air and 
indoor dust: occurrence, partitioning, and human expo-
sure. Environ Sci Technol 39(17):6599–6606.
Slotkin TA, MacKillop EA, Melnick RL, Thayer KA, Seidler FJ. 
2008. Developmental neurotoxicity of perfluorinated 
chemicals modeled in vitro. Environ Health Perspect 
116:716–722.
So MK, Taniyasu S, Yamashita N, Giesy JP, Zheng J, Fang Z, 
et al. 2004. Perfluorinated compounds in coastal waters of 
Hong Kong, South China, and Korea. Environ Sci Technol 
38(15):4056–4063.
Steenland K, Jin C, MacNeil J, Lally C, Ducatman A, Vieira V, 
et al. 2009. Predictors of PFOA levels in a community 
surrounding a chemical plant. Environ Health Perspect 
117:1083–1088.
Stevens J, Harman JS, Kelleher KJ. 2005. Race/ethnicity 
and insurance status as factors associated with ADHD 
treatment patterns. J Child Adolesc Psychopharmacol 
15(1):88–96.
Stock NL, Lau FK, Ellis DA, Martin JW, Muir DC, Mabury SA. 
2004. Polyfluorinated telomer alcohols and sulfonamides 
in the North American troposphere. Environ Sci Technol 
38(4):991–996.
Weitzman M, Gortmaker S, Sobol A. 1992. Maternal smoking and 
behavior problems of children. Pediatrics 90(3):342–349.
Wil l iams GM, O’Cal laghan M, Najman JM, Bor W, 
Andersen MJ, Richards D, et al. 1998. Maternal cigarette 
smoking and child psychiatric morbidity: a longitudinal 
study. Pediatrics 102(1):e11.
